New Drug-Discovery Method for Cancer Therapies

The company describes Chemetics as "a hybrid of proven wet chemistry and molecular biology approaches that enables the rapid synthesis and accurate selection of billions to trillions of chemically diverse, drug-like compounds in a single test tube.”

The library of more than 100 million compounds generated by Nuevolution has already yielded candidate drugs that inhibit the cancer related protein integrin avBeta3. Generation of the library and selection of the candidate drugs was accomplished in a matter of days using the Chemetics system.

"The generation of this unique ‘ultra-large' compound library and the subsequent rapid identification of novel high potency drug candidates clearly demonstrate the tremendous power of Chemetics and represent a major milestone to establishing Nuevolution as a leading drug discovery company,” said Dr. Zahed Subhan, CEO of Nuevolution A/S. "Chemetics is poised to truly revolutionize the drug discovery process. It is the only technology available today that successfully combines ultra-large libraries of billions to trillions of drug-like small molecules with an accurate selection method that can efficiently handle such enormous numbers of compounds.”





Related Links:
Nuevolution A/S